ONS CHEMOTHERAPY IMMUNOTHERAPY CERTIFICATE EXAM SCRIPT QUESTIONS WITH FULL SOLUTIONS 2026

ONS CHEMOTHERAPY IMMUNOTHERAPY
CERTIFICATE EXAM SCRIPT QUESTIONS WITH
FULL SOLUTIONS 2026


◉ What 6 patient characteristics make CINV more likely? Answer: 1.
Younger than 50 years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy


◉ Types of CINV: Answer: Acute
Delayed
Breakthrough
Anticipatory
Refractory


◉ Define acute CINV Answer: Occurring within 24 hours of
chemotherapy

,◉ Define delayed CINV Answer: Occurring from 24 hours to 5 days
after treatment


◉ Define breakthrough CINV Answer: Occurring despite treatment


◉ Define anticipatory CINV Answer: Triggered by taste, odor,
memories, visions, or anxiety related to chemotherapy


◉ Define refractory CINV Answer: Occurring during subsequent
cycles when treatment failed in earlier cycles


◉ Moderately emetogenic chemo (MEC) causes CINV in patients
___% to ___% of the time Answer: 30-90


◉ Patients on low-potential emetogenic chemo develop CINV ___%
to ___% of the time Answer: 10-30


◉ Minimal-risk emetogenic chemo causes CINV less than ___% of the
time Answer: 10


◉ Common IV HEC drugs include: Answer: Carmustine
Cisplatin

, Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin


◉ Common IV MEC drugs include: Answer: Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin


◉ Common low-potential IV emetogenic chemo drugs include:
Answer: 5-FU
Cytarabine
Docetaxel
Etoposide
Gemcitabine
Methotrexate